PursueCare
PursueCare offers telehealth addiction treatment and mental health services, focusing on substance use disorders and co-occurring mental health conditions, accessible via a smartphone app.
Services
PursueCare offers telehealth addiction treatment and mental health services that are accessible through a smartphone app. The company treats opioid, alcohol, and other substance use disorders, and also provides psychiatric treatment for co-occurring mental health conditions. Their comprehensive virtual clinic programs include medical care, addiction counseling and therapy, psychiatry, targeted case management, and pharmacy services. The company partners with hospitals, health systems, employers, and health plans to extend its virtual addiction treatment services.
Coverage and Accessibility
PursueCare’s services are available in Connecticut, Delaware, Florida, Kentucky, Maine, Massachusetts, New Hampshire, New Jersey, Ohio, Pennsylvania, and West Virginia. The company accepts most major insurances, including Medicare and Medicaid, and offers low-cost self-pay programs for uninsured or underinsured patients. This broad accessibility ensures that a wide range of patients can receive the necessary care without significant financial barriers.
Fundraising and Investments
PursueCare successfully completed a Series B fundraising round totaling $20 million. This investment round was led by T.Rx Capital and Yamaha Motor Ventures, showing significant investor confidence in the company's telehealth addiction treatment model and growth potential. The capital raised is expected to help PursueCare expand its services and integrate new technologies.
Digital Therapeutics Acquisitions
PursueCare has acquired several digital therapeutics to enhance its service offerings. These include reSET® and reSET-O® from Pear Therapeutics, Inc., which are FDA-authorized app-based treatments for substance use disorder (SUD) and opioid use disorder (OUD), respectively. Additionally, the company acquired reSET-A®, a digital therapeutic for alcohol use disorder that received FDA breakthrough device designation. These acquired digital therapeutics are integrated into PursueCare's comprehensive virtual clinic programs to provide a wider array of treatment options for their patients.